Tags

Type your tag names separated by a space and hit enter

[Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine].
An Esp Pediatr. 2002 Jan; 56(1):79-90.AE

Abstract

Pneumococcal disease is a major cause of morbidity, hospitalization and mortality. Two age groups show a greater incidence and severity of the disease: children under the age of 5 years (mainly during the first 2 years of life) and adults aged more than 65 years. The heptavalent pneumococcal conjugate vaccine, which was commercialized in Spain in June 2001, is efficacious in children aged less than 2 years and, unlike the non-conjugate 23-valent vaccine, it induces immunological memory. In Spain the heptavalent vaccine covers 80 % of serotypes causing pneumococcal invasive disease and acute otitis media in children aged 2-59 months. The heptavalent vaccine has been shown to be immunogenic, efficacious and safe. It has proven efficacy in the prevention of invasive disease caused by the seven vaccine serotypes. In addition, it significantly decreases pneumonia and also prevent acute otitis media. The vaccine is preferably indicated in children aged less than 2 years; children aged 2-5 years may also benefit from the vaccine but those in risk groups should be prioritized. Greater knowledge of the epidemiology of pneumococcal disease and the efficiency of this vaccine in Spain will determine whether it should be included in the immunization schedule.

Authors+Show Affiliations

Comité Asesor de Vacunas de la AEP, Barcelona, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

spa

PubMed ID

11792258

Citation

de Arístegui Fernández, J, et al. "[Pneumococcal Disease and Its Prevention. the Heptavalent Pneumococcal Conjugate Vaccine]." Anales Espanoles De Pediatria, vol. 56, no. 1, 2002, pp. 79-90.
de Arístegui Fernández J, Corretger Rauet JM, García Martín F, et al. [Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine]. An Esp Pediatr. 2002;56(1):79-90.
de Arístegui Fernández, J., Corretger Rauet, J. M., García Martín, F., Hernández-Sampelayo, T., Moraga Llop, F. A., Rodrigo Gonzalo De Liria, C., & Ruiz Contreras, J. (2002). [Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine]. Anales Espanoles De Pediatria, 56(1), 79-90.
de Arístegui Fernández J, et al. [Pneumococcal Disease and Its Prevention. the Heptavalent Pneumococcal Conjugate Vaccine]. An Esp Pediatr. 2002;56(1):79-90. PubMed PMID: 11792258.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pneumococcal disease and its prevention. The heptavalent pneumococcal conjugate vaccine]. AU - de Arístegui Fernández,J, AU - Corretger Rauet,J M, AU - García Martín,F, AU - Hernández-Sampelayo,T, AU - Moraga Llop,F A, AU - Rodrigo Gonzalo De Liria,C, AU - Ruiz Contreras,J, AU - ,, PY - 2002/1/17/pubmed PY - 2002/10/31/medline PY - 2002/1/17/entrez SP - 79 EP - 90 JF - Anales espanoles de pediatria JO - An Esp Pediatr VL - 56 IS - 1 N2 - Pneumococcal disease is a major cause of morbidity, hospitalization and mortality. Two age groups show a greater incidence and severity of the disease: children under the age of 5 years (mainly during the first 2 years of life) and adults aged more than 65 years. The heptavalent pneumococcal conjugate vaccine, which was commercialized in Spain in June 2001, is efficacious in children aged less than 2 years and, unlike the non-conjugate 23-valent vaccine, it induces immunological memory. In Spain the heptavalent vaccine covers 80 % of serotypes causing pneumococcal invasive disease and acute otitis media in children aged 2-59 months. The heptavalent vaccine has been shown to be immunogenic, efficacious and safe. It has proven efficacy in the prevention of invasive disease caused by the seven vaccine serotypes. In addition, it significantly decreases pneumonia and also prevent acute otitis media. The vaccine is preferably indicated in children aged less than 2 years; children aged 2-5 years may also benefit from the vaccine but those in risk groups should be prioritized. Greater knowledge of the epidemiology of pneumococcal disease and the efficiency of this vaccine in Spain will determine whether it should be included in the immunization schedule. SN - 0302-4342 UR - https://www.unboundmedicine.com/medline/citation/11792258/[Pneumococcal_disease_and_its_prevention__The_heptavalent_pneumococcal_conjugate_vaccine]_ L2 - https://medlineplus.gov/pneumococcalinfections.html DB - PRIME DP - Unbound Medicine ER -